Mobaraki et al 2010
Cancer science · 2010 · Japan · Carbon ion
The figures it reported
- yen6428 per 1% increase in survivalCIRT vs multimodality therapy
Figures are shown exactly as the paper gives them, in its own currency and price year. We do not convert between currencies: see the glossary for why.
- Patients modelled or enrolled
- 25 patients with isolated unresectable pelvic recurrence of rectal adenocarcinoma after radical surgery alone; 14 treated with CIRT at NIRS and 11 with multimodality therapy at Gunma University Hospital; treated 2003-2005, followed retrospectively
- Comparator
- Conventional multimodality therapy (three-dimensional conformal radiotherapy, chemotherapy, and hyperthermia)
- Indication
- Locally recurrent rectal cancer
- Study design
- Cost-effectiveness analysis; retrospective cohort of 25 patients (direct costs computed per individual); outcome measured as 2-year overall survival (ICER per 1% increase in survival)
- Time horizon
- 2 years of follow-up from the time of recurrence (direct costs computed for each patient over 2 years)
- Delivery technique
- not reported by this study
- Perspective
- not reported by this study
- Currency
- JPY
- Price year
- not reported by this study
- Willingness-to-pay threshold
- not reported by this study
- Discount rate
- not reported by this study
- Cost of the particle course assumed
- not reported by this study
- Cost of the comparator assumed
- not reported by this study
Whose costs were counted: a payer, a hospital, or society as a whole.
The year the costs are expressed in. Without it, a figure cannot be compared across time.
Reporting quality
57 out of 100 on the Quality of Health Economic Studies instrument, a 16-item checklist covering the objective, the perspective, the sources of each estimate, the handling of uncertainty, the horizon and discounting, how costs were measured, the model's transparency, the discussion of bias, and whether funding was disclosed. It measures how well the study was reported, not whether its conclusion is correct: a well-reported study can still reach a conclusion a later trial overturns.